Every one of those 1 sits in a single category, pharma. Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 1 of these 1 story. Arbutus Biopharma appears in 1 tracked Biotech story from March 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Arbutus Biopharma
Every one of those 1 sits in a single category, pharma. Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 1 of these 1 story. Arbutus Biopharma appears in 1 tracked Biotech story from March 4, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Arbutus Biopharma. Shared-story counts are live from our verified record — not editorial picks.
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
Arbutus Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.